# NEWAMSTERDAM PHARMA COMPANY \*W EXP 99/99/999

NEWAMSTERDAM PHARMA COMPANY *W EXP 99/99/999 is a security (CUSIP N62509117) tracked across SEC portfolio filings. 12 institutional managers reported $27.4M on Form 13F as of 2026-03-31.

## Summary

- Issuer: NEWAMSTERDAM PHARMA COMPANY
- Class: \*W EXP 99/99/999
- CUSIP: N62509117
- 13F holders: 12
- 13F value: $27.4M
- 13F period: 2026-03-31
- N-PORT fund positions: 0

## Top institutional holders (Form 13F)

| Manager | Location | Value | Shares |
| --- | --- | --- | --- |
| [Frazier Life Sciences Management, L.P.](https://search.stillhousedata.com/firm/317522) | MENLO PARK, CA | $10.0M | 500,333 |
| RA CAPITAL MANAGEMENT, L.P. | Boston, MA | $6.7M | 333,333 |
| [Affinity Asset Advisors, LLC](https://search.stillhousedata.com/firm/312788) | New York, NY | $4.9M | 245,000 |
| Bain Capital Life Sciences Investors, LLC | Boston, MA | $2.0M | 99,999 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | New York, NY | $1.9M | 92,787 |
| MILLENNIUM MANAGEMENT LLC | NEW YORK, NY | $1.5M | — |
| ARISTEIA CAPITAL LLC | GREENWICH, CT | $343K | 15,708 |
| [WOLVERINE ASSET MANAGEMENT LLC](https://search.stillhousedata.com/firm/138907) | CHICAGO, IL | $43K | 2,127 |
| CIBC Private Wealth Group, LLC | ATLANTA, GA | $25K | 1,000 |
| UBS Group AG | Zurich, V8 | $8K | 396 |
| Vestcor Inc | FREDERICTON, A3 | $131 | 6,666 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | BIRMINGHAM, AL | — | 0 |

## More

- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/security/N62509117.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.